These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 19828607)

  • 21. SCF
    Li F; Mladenov E; Mortoga S; Iliakis G
    Cell Death Dis; 2020 Jul; 11(7):548. PubMed ID: 32683422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD28 costimulation mediates transcription of SKP2 and CKS1, the substrate recognition components of SCFSkp2 ubiquitin ligase that leads p27kip1 to degradation.
    Appleman LJ; Chernova I; Li L; Boussiotis VA
    Cell Cycle; 2006 Sep; 5(18):2123-9. PubMed ID: 16969077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulation of Skp2 levels by the Pim-1 protein kinase.
    Cen B; Mahajan S; Zemskova M; Beharry Z; Lin YW; Cramer SD; Lilly MB; Kraft AS
    J Biol Chem; 2010 Sep; 285(38):29128-37. PubMed ID: 20663873
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early mitotic inhibitor-1, an anaphase-promoting complex/cyclosome inhibitor, can control tumor cell proliferation in hepatocellular carcinoma: correlation with Skp2 stability and degradation of p27(Kip1).
    Zhao Y; Tang Q; Ni R; Huang X; Wang Y; Lu C; Shen A; Wang Y; Li C; Yuan Q; Chen H; Cheng C; He S
    Hum Pathol; 2013 Mar; 44(3):365-73. PubMed ID: 22995332
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Degradation of Tob1 mediated by SCFSkp2-dependent ubiquitination.
    Hiramatsu Y; Kitagawa K; Suzuki T; Uchida C; Hattori T; Kikuchi H; Oda T; Hatakeyama S; Nakayama KI; Yamamoto T; Konno H; Kitagawa M
    Cancer Res; 2006 Sep; 66(17):8477-83. PubMed ID: 16951159
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The G1 phase E3 ubiquitin ligase TRUSS that gets deregulated in human cancers is a novel substrate of the S-phase E3 ubiquitin ligase Skp2.
    Jamal A; Swarnalatha M; Sultana S; Joshi P; Panda SK; Kumar V
    Cell Cycle; 2015; 14(16):2688-700. PubMed ID: 26038816
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting the untargetable: RB1-deficient tumours are vulnerable to Skp2 ubiquitin ligase inhibition.
    Gupta P; Zhao H; Hoang B; Schwartz EL
    Br J Cancer; 2022 Oct; 127(6):969-975. PubMed ID: 35752713
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The E3 ubiquitin ligase skp2 regulates neural differentiation independent from the cell cycle.
    Boix-Perales H; Horan I; Wise H; Lin HR; Chuang LC; Yew PR; Philpott A
    Neural Dev; 2007 Dec; 2():27. PubMed ID: 18081928
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phosphorylation of Skp2 regulated by CDK2 and Cdc14B protects it from degradation by APC(Cdh1) in G1 phase.
    Rodier G; Coulombe P; Tanguay PL; Boutonnet C; Meloche S
    EMBO J; 2008 Feb; 27(4):679-91. PubMed ID: 18239684
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tuberin binds p27 and negatively regulates its interaction with the SCF component Skp2.
    Rosner M; Hengstschläger M
    J Biol Chem; 2004 Nov; 279(47):48707-15. PubMed ID: 15355997
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PDZRN3/LNX3 is a novel target of human papillomavirus type 16 (HPV-16) and HPV-18 E6.
    Thomas M; Banks L
    J Virol; 2015 Jan; 89(2):1439-44. PubMed ID: 25355882
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of the SCFSkp2 ubiquitin ligase in the degradation of p21Cip1 in S phase.
    Bornstein G; Bloom J; Sitry-Shevah D; Nakayama K; Pagano M; Hershko A
    J Biol Chem; 2003 Jul; 278(28):25752-7. PubMed ID: 12730199
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Abrogation of the Brd4-positive transcription elongation factor B complex by papillomavirus E2 protein contributes to viral oncogene repression.
    Yan J; Li Q; Lievens S; Tavernier J; You J
    J Virol; 2010 Jan; 84(1):76-87. PubMed ID: 19846528
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mapping the interactome of HPV E6 and E7 oncoproteins with the ubiquitin-proteasome system.
    Poirson J; Biquand E; Straub ML; Cassonnet P; Nominé Y; Jones L; van der Werf S; Travé G; Zanier K; Jacob Y; Demeret C; Masson M
    FEBS J; 2017 Oct; 284(19):3171-3201. PubMed ID: 28786561
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The E2F5 repressor is an activator of E6/E7 transcription and of the S-phase entry in HPV18-associated cells.
    Teissier S; Pang CL; Thierry F
    Oncogene; 2010 Sep; 29(36):5061-70. PubMed ID: 20639900
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulation of human papillomavirus type 16 E7 activity through direct protein interaction with the E2 transcriptional activator.
    Gammoh N; Grm HS; Massimi P; Banks L
    J Virol; 2006 Feb; 80(4):1787-97. PubMed ID: 16439535
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-risk but not low-risk HPV E2 proteins bind to the APC activators Cdh1 and Cdc20 and cause genomic instability.
    Bellanger S; Blachon S; Mechali F; Bonne-Andrea C; Thierry F
    Cell Cycle; 2005 Nov; 4(11):1608-15. PubMed ID: 16222116
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways.
    Goodwin EC; DiMaio D
    Proc Natl Acad Sci U S A; 2000 Nov; 97(23):12513-8. PubMed ID: 11070078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protein tyrosine phosphatase H1 is a target of the E6 oncoprotein of high-risk genital human papillomaviruses.
    Töpffer S; Müller-Schiffmann A; Matentzoglu K; Scheffner M; Steger G
    J Gen Virol; 2007 Nov; 88(Pt 11):2956-2965. PubMed ID: 17947517
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Skp2 in the ubiquitin-proteasome system: A comprehensive review.
    Asmamaw MD; Liu Y; Zheng YC; Shi XJ; Liu HM
    Med Res Rev; 2020 Sep; 40(5):1920-1949. PubMed ID: 32391596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.